Moderna, Inc. (0A45.IL)
| Previous close | 102.81 |
| Open | 0.00 |
| Bid | 101.56 x N/A |
| Ask | 106.76 x N/A |
| Day's range | 104.89 - 104.89 |
| 52-week range | 62.55 - 142.32 |
| Volume | |
| Avg. volume | 17,893 |
| Market cap | 50.997B |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | 39.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
mRNA Platform Global Strategic Research Report 2024
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The report delves into the mRNA platform, examining its global competitive landscape and the market presence of key players. It provides a conceptual understanding of mRNA, highlighting its revolutionary approach to medicine and the significant scientific breakthroughs it represents. The introduction of mRNA vaccines is explored, emphasizing
- ACCESSWIRE
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against ...
- PR Newswire
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage
